All News

fence

The Fallacy of Biologic Treatment to Prevent Rheumatoid Arthritis

Richard Conway, MBBChBAO, PhD

The window of opportunity concept in RA shifted our focus to trying to treat disease earlier and more aggressively to improve long term outcomes. A natural development of this was to reconsider the possibility of therapeutic interventions aimed at the prevention of rheumatoid arthritis.

Read Article
psA.fil_.Hands_.jpg

Bimekizumab is Coming… in Third Place

Michael Putman, MD, MSCI

Of the many exciting advancements for patients with psoriatic arthritis at ACR Convergence, one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab. Nearly two dozen bimekizumab abstracts will be featured at this year’s meeting and it recently received authorization in Europe and the U.S. for psoriasis. That makes this the year I plan to figure out where this drug will be useful for my patients with PsA. 

Read Article
lung%2Cbright.jpg

Pulmonary Manifestations of Rheumatic Disease in Asymptomatic Patients

Meral K. El Ramahi, MD, FACP, FACR

In clinical practice, pulmonary manifestations of rheumatic medical diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and peripheral spondyloarthritis (pSpA) are typically not screened for upon diagnosis of a rheumatic disease in patients without any signs or symptoms suggest

Read Article
steroids.prednisone.pills_.jpg

Glucocorticoids-free zone in SLE?

Md Yuzaiful Md Yusof, MRCP(UK), PhD

For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE. They are classically used to not only induce remission or treat an acute flare, but also as maintenance therapy. They are a valuable 'friend' if used wisely, and can become a 'foe' if used excessively.

Read Article
pregnant, pregnancy, mother, fertility

Pregnancy Updates That Will Change The Way I Practice

Rachel Tate, DO

ACR Convergence is truly drinking from the proverbial fire hose. It’s a beautiful mash-up of basic science and treatment updates meets guidelines, recommendations, and disease identification.

Read Article
RA.Ow02.jpg

Towards Personalised Care in Rheumatoid Arthritis

Antoni Chan, MD, PhD

Since the millennium, we have seen an expansion in the number of advanced treatments both biologic and targeted synthetic disease modifying anti-rheumatic drugs for rheumatoid arthritis. The challenge remains on how best to characterise the subtypes of RA in order to choose the best drug to ensure optimal outcome for patients. 

Read Article
#obesity is a significant RF for #osteoarthritis Assoc'd with: 💠impairment of gut biota 💠microbial translocation Leads to innate immune activation #ACR23 @RheumNow @rheumarhyme https://t.co/iuEvBh3A1j
sheila  ( View Tweet)
Which to use in #EGPA? #Mepolizumab IL5i vs Benralizumab = monoclonal Ab binding to IL5Ralpha. Noninferiority RCT - both are similar. Is more Impt ? IL5 drug vs #Rituximab or #Cyclo for severe Eosinoph granuloma todos w polyangiitis 🤷 #ACR23 ⁦@RheumNow⁩ ⁦@ACRheum⁩ https://t.co/zyZeHHSsck
Janet Pope  ( View Tweet)
We gotta do better! Reproductive health counseling is poorly done- only a third rheumatologists surveyed ask pts about reproductive health: sexual activity, pregnancy desire, contraception. Abstr#0162 @_michgarcia @rheumnow #ACR23 https://t.co/r9tewu2I9N
TheDaoIndex KDAO2011 ( View Tweet)
Prof Mustelin explains why Basic Science research is important in medicine. New ideas need: 👉discovery 👉explanation 👉 impact #ACR23 @rheumnow #YearInReview #BasicScience https://t.co/t0W3GdUtWD
TheDaoIndex KDAO2011 ( View Tweet)
Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/0RDwTdzhwS
Dr. John Cush RheumNow ( View Tweet)
Following on from the #ACR23 keynote, a deeper dive on how AI might actually help clinical rheumatologists in real life, from clinical rheumatologist @DrCMcMaster @DT4Health et al in @ACR_Journals: https://t.co/dQJzTwScy0 @RheumNow

David Liew drdavidliew ( View Tweet)

#ACR23 Abstr#PP12 "I am stronger than my disease & won’t let it stop me from leading a fulfilling life!"- a person with #Sjogren shared tips on lifestyle modification to help fatigue. - schedule appointments in the morning - exercise - keep a diary - listen to body @RheumNow https://t.co/8ROFrDvPS1
Md Yuzaiful Md Yusof  ( View Tweet)
AI is here to stay, like it or not. Some words to ponder on👇 #ACR23 @RheumNow @rheumarhyme https://t.co/2K3Qc0Il8i
sheila  ( View Tweet)
"Machines don't decide, they make predictions..-Dr. Avi Goldfarb As a parting note, he leaves the audience some Qs: "In your orgs/institutions, how much of what you do is really about delivering value? Or serving patients & other stakeholders?" #ACR23 @RheumNow @rheumarhyme https://t.co/xnFeQgDPco
sheila  ( View Tweet)
This is what exactly what AI should mean for clinical rheumatologists: discard the mundane & repetitive enhance/make time the value add Rheumatologists are really good at the value add, and we dislike the mundane & repetitive. We should embrace what is to come. #ACR23 @RheumNow https://t.co/6Lb2ihlPFF

David Liew drdavidliew ( View Tweet)

What diseases will you follow presentations on at #ACR23? @RheumNow @ACRheum

Janet Pope  ( View Tweet)

Keynote speaker #ACR23 @avicgoldfarb Giving history of AI- imagenet, AI start ups...and Now ChatGPT! @RheumNow https://t.co/h2sOD7hjaF
Bella Mehta bella_mehta ( View Tweet)
Understanding placebo effects is very important for any clinical research! This book will lay down important concepts in this. And fully accessible in a few weeks! @RheumNow #ACR23 https://t.co/J3grEhP460
Bella Mehta bella_mehta ( View Tweet)
Little disturbing to see the data that most patients using cannabis dont know what exact product they are using. Also not most is not prescribed/ illegal! Lots to learn and may have potential but need to be careful! @RheumNow #ACR23 https://t.co/Y0vHmVvWdL
Bella Mehta bella_mehta ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×